In this article, we will discuss the 12 Best Get Rich Quick Stocks to Buy According to Hedge Funds.

On March 9, Main Management CEO and Portfolio Manager Kim Arthur joined CNBC’s ‘Halftime Report’ to talk about what he’s seeing in his sector rotation fund, and whether the volatility is exacerbating that trend or reversing it amid the turmoil in the Middle East. Arthur explained that a major mix shift began in the market last October. He described this shift as a move away from asset-light sectors (specifically technology, communications, and consumer discretionary) and toward asset-heavy sectors (including basic materials, industrials, and energy). He used a physical analogy for these asset-heavy plays and noted they consist of items from the periodic table that would cause physical pain if dropped on one’s toe.

Despite the recent sidetrack caused by the attacks and war in the Middle East involving Iran, Arthur maintained that the rotation thesis remains intact. He highlighted that asset-heavy plays have significantly outperformed asset-light sectors, leading them by approximately 15 points year-to-date. He believes that once the immediate geopolitical conflict passes, this trend will continue. Regarding the future of the tech trade and whether investors will return to it out of muscle memory, Arthur clarified that tech is not dead and expects it to perform okay. However, he emphasized that the cycle favoring asset-heavy plays is likely to be long-dated. He attributed this longevity to structural trends such as the massive build-out of data centers, the on-shoring of manufacturing, and the physical requirements of buying land and putting steel in the ground.

That being said, we’re here with a list of the 12 best get-rich-quick stocks to buy according to hedge funds.

Our Methodology

We sifted through financial media reports to compile a list of stocks discussed for making you rich, and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.

Note: All data was sourced on March 13. 

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

12 Best Get Rich Quick Stocks to Buy According to Hedge Funds

12. Bicycle Therapeutics (NASDAQ:BCYC)

Number of Hedge Fund Holders: 23

Bicycle Therapeutics (NASDAQ:BCYC) is one of the best get-rich-quick stocks to buy according to hedge funds. On February 3, Bicycle Therapeutics announced several key leadership transitions as the company enters a new phase of innovation for its proprietary bicyclic peptide technology. Travis Thompson, who joined the firm in 2018 and previously served as senior vice president and chief accounting officer, has been appointed as the new chief financial officer. He succeeds Alethia Young, who will transition into an advisory role after a three-month interim period. Thompson’s new responsibilities include overseeing finance, accounting, and investor relations.

In the clinical and scientific departments, Michael Method, M.D., MPH, MBA, has been promoted to chief medical officer, taking over for Eric Westin, M.D., who is retiring from the role. Dr. Method, an oncologist who joined the company in 2025, will now lead clinical development and manage the Clinical Advisory Board. Additionally, Michael Skynner, Ph.D., a veteran of the company since 2016, is moving from his role as chief technology officer to become the chief scientific officer. Dr. Skynner will focus on scientific discovery, early-stage pipeline development, and the Research & Innovation Advisory Board.

CEO Kevin Lee, Ph.D., stated that these leadership changes are intended to build momentum across the company’s oncology pipeline and create shareholder value following significant progress in 2025. The company highlighted its strengthened operational capacity and a financial runway expected to last into 2028. Moving forward, the executive team aims to advance targeted oncology clinical programs and recently established radiopharmaceutical strategic partnerships to improve patient outcomes.

Bicycle Therapeutics (NASDAQ:BCYC) is a clinical-stage pharmaceutical company that develops a class of medicines for diseases that are underserved by existing therapeutics in the US and the UK.

11. ACM Research Inc. (NASDAQ:ACMR)

Number of Hedge Fund Holders: 32

ACM Research Inc. (NASDAQ:ACMR) is one of the best get-rich-quick stocks to buy according to hedge funds. On February 26, ACM Research achieved record annual revenue of $901.3 million in 2025, representing a 15% increase year-over-year. This was driven by a cleaning portfolio and the expansion of proprietary technologies like high-temperature furnace platforms. While full-year revenue was strong, Q4 saw a more moderate revenue increase of 9.4% to $244.4 million.

2025 was a year of geographic and product expansion. ACM made progress in global markets, delivering its first single-wafer cleaning systems to a foundry in Singapore and securing multiple orders for wafer-level and panel-level packaging tools from North American and Southeast Asian customers. The company also reached technical milestones with the delivery of its first Ultra ECP ap-p horizontal panel-level plating tool and the Ultra Lith BK photoresist hardening tool. To support this global scaling, ACM is accelerating investments in its Oregon facility, expected to begin operations in H2 2026.

The company entered 2026 with a strengthened balance sheet, reporting $845 million in net cash following a private offering by its Shanghai subsidiary and a subsequent share sale in early 2026. Looking ahead, ACM Research Inc. (NASDAQ:ACMR) maintained its 2026 revenue guidance of $1.08 billion to $1.175 billion, projecting growth between 21% and 30%.

ACM Research Inc. (NASDAQ:ACMR), together with its subsidiaries, develops, manufactures, and sells capital equipment in Mainland China and internationally. It also develops, manufactures, and sells a range of packaging tools to wafer assembly and packaging customers.

10. Iovance Biotherapeutics Inc. (NASDAQ:IOVA)

Number of Hedge Fund Holders: 33

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best get-rich-quick stocks to buy according to hedge funds. On February 24, Iovance Biotherapeutics announced positive early data from a pilot clinical trial evaluating its lifileucel TIL cell therapy in patients with advanced soft tissue sarcomas. The study focused on individuals with metastatic or unresectable undifferentiated pleomorphic sarcoma/UPS and dedifferentiated liposarcoma/DDLPS who had failed at least one prior systemic treatment.

Among the first six evaluable patients, the therapy demonstrated a 50% objective response rate, with patients experiencing deep responses that improved over time despite a high baseline disease burden and multiple prior lines of therapy. Iovance Biotherapeutics Inc. (NASDAQ:IOVA) highlighted a significant unmet medical need for these aggressive cancers, which affect over 8,000 patients annually across the US and Europe. Current second-line treatment options typically yield response rates of less than 5%, with median overall survival often falling under one year.

Medical experts involved in the trial noted that this one-time immunotherapy treatment showed unprecedented results for refractory patients who previously relied on chemotherapy with limited efficacy. The safety profile observed in the study was favorable and remained consistent with lifileucel’s performance in other solid tumors like melanoma and lung cancer. Following these results, Iovance plans to launch a single-arm registrational trial for second-line advanced UPS and DDLPS in Q2 2026.

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is a commercial-stage biopharmaceutical company that develops and commercializes cell therapies using autologous tumor-infiltrating lymphocytes for the treatment of metastatic melanoma and other solid tumor cancers in the US and internationally.

9. Iren Limited (NASDAQ:IREN)

Number of Hedge Fund Holders: 46

Iren Limited (NASDAQ:IREN) is one of the best get-rich-quick stocks to buy according to hedge funds. On March 4, Iren announced the purchase of over 50,000 NVIDIA B300 GPUs, a move that will expand its total fleet to 150,000 units. The company aims to deploy these additional GPUs in phases throughout H2 2026 across its existing air-cooled data centers in Mackenzie, British Columbia, and Childress, Texas. This expansion is designed to address the growing demand for time-to-compute in the AI cloud market, allowing the firm to bring capacity online with greater speed and certainty for its customers.

Financially, Iren expects this 150,000 GPU fleet to support an annualized run-rate revenue of over $3.7 billion by the end of 2026. The company has secured $9.3 billion in funding over the last eight months through various channels, including customer prepayments, convertible notes, and GPU leasing. About $3.5 billion in additional capital expenditure is planned for H2 2026 to cover the costs of GPUs, servers, networking, and labor. To enhance working capital efficiency, payment terms for the hardware have been structured on a post-shipment basis.

To complement its existing funding sources, Iren Limited (NASDAQ:IREN) has also established an at-the-market equity program as part of its broader capital management strategy. Co-CEO Daniel Roberts noted that scaling to this capacity positions the company as one of the largest global providers of AI cloud infrastructure.

Iren Limited (NASDAQ:IREN) operates in the vertically integrated data center business in Australia and Canada. The company owns & operates computing hardware, as well as electrical infrastructure & data centers. It also mines Bitcoin.

8. Duolingo Inc. (NASDAQ:DUOL)

Number of Hedge Fund Holders: 51

Duolingo Inc. (NASDAQ:DUOL) is one of the best get-rich-quick stocks to buy according to hedge funds. On February 26, Duolingo reached financial milestones in 2025, surpassing $1 billion in bookings and $300 million in adjusted EBITDA. The company also reached a record 50 million DAUs, a 5x increase since its 2021 IPO. Despite these achievements, management noted a deceleration in user growth throughout the year, prompting a shift toward aggressive reinvestment. To lead this transition, the company welcomed Gillian Munson as the new CFO, succeeding Matt Skaruppa.

For 2026, Duolingo Inc. (NASDAQ:DUOL) prioritized growing-the-pie by focusing on teaching quality and user acquisition. The company set a medium-term goal to reach 100 million DAUs by 2028. Key initiatives for the coming year include enhancing the free user experience and scaling newer subjects like math, music, and chess. To support these goals, Duolingo plans to share AI-powered features with a larger portion of its user base, a move expected to increase the cost of goods sold and lower overall gross margins in the short term.

The financial guidance for 2026 reflects this foundational year approach, with projected bookings growth of 10% to 12% and revenue growth of 15% to 18%. Adjusted EBITDA margins are expected to land around 25%, as spending on R&D and marketing is anticipated to outpace revenue growth. Additionally, the board has authorized a $400 million share buyback program to be executed over the coming year.

Duolingo Inc. (NASDAQ:DUOL) operates as a mobile learning platform in the US, the UK, and internationally.

7. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Number of Hedge Fund Holders: 63

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best get-rich-quick stocks to buy according to hedge funds. On February 27, the US FDA approved BioMarin’s supplemental Biologics License Application for PALYNZIQ, expanding its use to include adolescents aged 12 and older with phenylketonuria/PKU. This medication remains the only approved enzyme substitution therapy designed to reduce blood phenylalanine/Phe concentrations in patients with this rare genetic condition.

The approval is particularly significant for teenagers, as the restrictive dietary management required for PKU often becomes difficult to maintain during adolescence, leading to potential neurocognitive issues if blood Phe levels remain uncontrolled. Data from the Phase 3 PEGASUS study supported this decision, demonstrating that PALYNZIQ achieved statistically significant reductions in blood Phe levels compared to diet alone.

The safety profile for adolescents was found to be consistent with previous studies in adults, with common side effects including injection site reactions, joint pain, and headaches. Owing to the risk of anaphylaxis, the therapy is administered through a restricted program under a Risk Evaluation and Mitigation Strategy/REMS. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is currently pursuing a similar expansion of the drug’s label with the European Medicines Agency to reach the adolescent population in the European Union.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biotechnology company that develops and commercializes therapies for life-threatening rare diseases and medical conditions in the US, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.

6. International Business Machines Corporation (NYSE:IBM)

Number of Hedge Fund Holders: 63

International Business Machines Corporation (NYSE:IBM) is one of the best get-rich-quick stocks to buy according to hedge funds. On March 12, IBM unveiled the industry’s first quantum-centric supercomputing reference architecture, providing a blueprint for integrating quantum processors/QPUs with traditional CPUs and GPUs. This new architecture creates a unified environment across on-premises systems and the cloud, allowing different computing types to work together on complex scientific challenges.

By using open software frameworks like Qiskit, IBM is enabling researchers to access quantum capabilities through familiar workflows to solve problems in chemistry, optimization, and materials science. The announcement highlights several successful applications of this architecture in high-level research. For example, a global team of researchers recently used a quantum-centric supercomputer to create and verify a half-Möbius molecule, while the Cleveland Clinic simulated a 303-atom mini-protein.

The company’s global ecosystem of partners is working to refine how these workflows are scheduled and orchestrated. Collaborative efforts with institutions like Rensselaer Polytechnic Institute are focused on improving the seamless management of tasks between quantum and HPC resources. As these algorithms and systems mature, International Business Machines Corporation (NYSE:IBM) expects a new wave of applications that can scale exponentially, pushing the boundaries of what is possible in molecular simulation and engineering.

International Business Machines Corporation (NYSE:IBM), together with its subsidiaries, provides integrated solutions and services in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through Software, Consulting, Infrastructure, and Financing segments.

Click to continue reading and see the 5 Best Get Rich Quick Stocks to Buy According to Hedge Funds.

Disclosure: None. None. Follow Insider Monkey on Google News.